Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05970302 | XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC | unknown | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05951127 | Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC(LEO) | active not recruiting | N/A | 141 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Jul 18, 2023 |
| clinicaltrials |
| NCT05911152 | Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study(SELECTED) | unknown | — | 2,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05904015 | The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05815290 | Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05815303 | XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | unknown | Phase 2 | 92 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05783089 | MSLN-targeted CAR-T Cells in Solid Tumors. | not yet recruiting | Phase 1 | 87 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Mar 24, 2023 | clinicaltrials |
| NCT05774171 | To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2 | unknown | — | 700 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients(UNIQUE) | recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05749016 | Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05747313 | Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05747326 | Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05609058 | The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target | unknown | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05681728 | A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer | unknown | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT05607225 | Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients | unknown | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05603078 | A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)(BIRKIN) | recruiting | N/A | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05587452 | Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence(RECOMMEND) | unknown | — | 950 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05511051 | A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy | unknown | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05497739 | Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer | unknown | Phase 2 | 68 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT05448885 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2022 | clinicaltrials |
| NCT05443672 | Multi-center Study of Deep Learning AI in Breast Mass | unknown | — | 1,122 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 5, 2022 | clinicaltrials |
| NCT05431504 | The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | not yet recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05392699 | ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer(AMENDER) | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05331326 | A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | unknown | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05327517 | Surgery or Chemoradiotherapy for Cervical Esophageal Cancer | recruiting | N/A | 192 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04099589 | Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma | unknown | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05289726 | Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 | unknown | Phase 2 | 152 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT04389073 | Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine | unknown | Phase 2 | 138 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05167149 | Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer | unknown | N/A | 144 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT04970043 | Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment | unknown | N/A | 58 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 21, 2021 | clinicaltrials |
| NCT04822792 | Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT(PRESCIENT) | unknown | — | 11,879 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04850027 | MRI-guided Lateral Lymph Node Dissection in Rectal Cancer | unknown | — | 268 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04850040 | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | unknown | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Apr 20, 2021 | clinicaltrials |
| NCT02861196 | Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer | completed | N/A | 59 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | unknown | Phase 2 | 74 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Sep 9, 2020 | clinicaltrials |
| NCT04498793 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04500704 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC(ACROSS1) | unknown | Phase 3 | 166 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500717 | Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation(ACROSS2) | unknown | Phase 3 | 460 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03575806 | Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection | completed | Phase 2 | 52 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT04125849 | Mediastinoscopy-assisted Transhiatal Esophagectomy Versus Thoraco-laparoscopic Esophagectomy for Esophageal Cancer | unknown | N/A | 160 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 15, 2020 | clinicaltrials |
| NCT04068090 | Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer | unknown | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT04213937 | Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 386 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT03772496 | Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells)(CTCs) | unknown | N/A | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03016364 | Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain | unknown | Phase 1 / Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | unknown | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT03137368 | A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）(STEP) | unknown | Phase 3 | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT03392220 | A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer | unknown | N/A | 308 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 9, 2018 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials